Drug repositioning via host-pathogen protein-protein interactions for the treatment of cervical cancer
IntroductionIntegrating interaction data with biological knowledge can be a critical approach for drug development or drug repurposing. In this context, host-pathogen-protein-protein interaction (HP-PPI) networks are useful instrument to uncover the phenomena underlying therapeutic effects in infect...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1096081/full |
| _version_ | 1797943594312531968 |
|---|---|
| author | Medi Kori Beste Turanli Kazim Yalcin Arga Kazim Yalcin Arga |
| author_facet | Medi Kori Beste Turanli Kazim Yalcin Arga Kazim Yalcin Arga |
| author_sort | Medi Kori |
| collection | DOAJ |
| description | IntroductionIntegrating interaction data with biological knowledge can be a critical approach for drug development or drug repurposing. In this context, host-pathogen-protein-protein interaction (HP-PPI) networks are useful instrument to uncover the phenomena underlying therapeutic effects in infectious diseases, including cervical cancer, which is almost exclusively due to human papillomavirus (HPV) infections. Cervical cancer is one of the second leading causes of death, and HPV16 and HPV18 are the most common subtypes worldwide. Given the limitations of traditionally used virus-directed drug therapies for infectious diseases and, at the same time, recent cancer statistics for cervical cancer cases, the need for innovative treatments becomes clear.MethodsAccordingly, in this study, we emphasize the potential of host proteins as drug targets and identify promising host protein candidates for cervical cancer by considering potential differences between HPV subtypes (i.e., HPV16 and HPV18) within a novel bioinformatics framework that we have developed. Subsequently, subtype-specific HP-PPI networks were constructed to obtain host proteins. Using this framework, we next selected biologically significant host proteins. Using these prominent host proteins, we performed drug repurposing analysis. Finally, by following our framework we identify the most promising host-oriented drug candidates for cervical cancer.ResultsAs a result of this framework, we discovered both previously associated and novel drug candidates, including interferon alfacon-1, pimecrolimus, and hyaluronan specifically for HPV16 and HPV18 subtypes, respectively.DiscussionConsequently, with this study, we have provided valuable data for further experimental and clinical efforts and presented a novel bioinformatics framework that can be applied to any infectious disease. |
| first_indexed | 2024-04-10T20:26:40Z |
| format | Article |
| id | doaj.art-abe358bd43ba4c3aa3ffbfa063a62e77 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T20:26:40Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-abe358bd43ba4c3aa3ffbfa063a62e772023-01-25T10:36:25ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-01-011310.3389/fonc.2023.10960811096081Drug repositioning via host-pathogen protein-protein interactions for the treatment of cervical cancerMedi Kori0Beste Turanli1Kazim Yalcin Arga2Kazim Yalcin Arga3Department of Bioengineering, Faculty of Engineering, Marmara University, Istanbul, TürkiyeDepartment of Bioengineering, Faculty of Engineering, Marmara University, Istanbul, TürkiyeDepartment of Bioengineering, Faculty of Engineering, Marmara University, Istanbul, TürkiyeGenetic and Metabolic Diseases Research and Investigation Center (GEMHAM), Marmara University, Istanbul, TürkiyeIntroductionIntegrating interaction data with biological knowledge can be a critical approach for drug development or drug repurposing. In this context, host-pathogen-protein-protein interaction (HP-PPI) networks are useful instrument to uncover the phenomena underlying therapeutic effects in infectious diseases, including cervical cancer, which is almost exclusively due to human papillomavirus (HPV) infections. Cervical cancer is one of the second leading causes of death, and HPV16 and HPV18 are the most common subtypes worldwide. Given the limitations of traditionally used virus-directed drug therapies for infectious diseases and, at the same time, recent cancer statistics for cervical cancer cases, the need for innovative treatments becomes clear.MethodsAccordingly, in this study, we emphasize the potential of host proteins as drug targets and identify promising host protein candidates for cervical cancer by considering potential differences between HPV subtypes (i.e., HPV16 and HPV18) within a novel bioinformatics framework that we have developed. Subsequently, subtype-specific HP-PPI networks were constructed to obtain host proteins. Using this framework, we next selected biologically significant host proteins. Using these prominent host proteins, we performed drug repurposing analysis. Finally, by following our framework we identify the most promising host-oriented drug candidates for cervical cancer.ResultsAs a result of this framework, we discovered both previously associated and novel drug candidates, including interferon alfacon-1, pimecrolimus, and hyaluronan specifically for HPV16 and HPV18 subtypes, respectively.DiscussionConsequently, with this study, we have provided valuable data for further experimental and clinical efforts and presented a novel bioinformatics framework that can be applied to any infectious disease.https://www.frontiersin.org/articles/10.3389/fonc.2023.1096081/fullhost-oriented drugshost-pathogen protein-protein interactionscervical cancerHPVdrug repurposing |
| spellingShingle | Medi Kori Beste Turanli Kazim Yalcin Arga Kazim Yalcin Arga Drug repositioning via host-pathogen protein-protein interactions for the treatment of cervical cancer Frontiers in Oncology host-oriented drugs host-pathogen protein-protein interactions cervical cancer HPV drug repurposing |
| title | Drug repositioning via host-pathogen protein-protein interactions for the treatment of cervical cancer |
| title_full | Drug repositioning via host-pathogen protein-protein interactions for the treatment of cervical cancer |
| title_fullStr | Drug repositioning via host-pathogen protein-protein interactions for the treatment of cervical cancer |
| title_full_unstemmed | Drug repositioning via host-pathogen protein-protein interactions for the treatment of cervical cancer |
| title_short | Drug repositioning via host-pathogen protein-protein interactions for the treatment of cervical cancer |
| title_sort | drug repositioning via host pathogen protein protein interactions for the treatment of cervical cancer |
| topic | host-oriented drugs host-pathogen protein-protein interactions cervical cancer HPV drug repurposing |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1096081/full |
| work_keys_str_mv | AT medikori drugrepositioningviahostpathogenproteinproteininteractionsforthetreatmentofcervicalcancer AT besteturanli drugrepositioningviahostpathogenproteinproteininteractionsforthetreatmentofcervicalcancer AT kazimyalcinarga drugrepositioningviahostpathogenproteinproteininteractionsforthetreatmentofcervicalcancer AT kazimyalcinarga drugrepositioningviahostpathogenproteinproteininteractionsforthetreatmentofcervicalcancer |